The genitourinary cancers condition center is a comprehensive resource for clinical news and expert insights on genitourinary cancers. Read more at OncLive.
June 1st 2025
Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.
First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.
May 31st 2025
Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.
May 30th 2025
Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.
May 29th 2025
Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.
May 28th 2025
Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.
May 27th 2025
I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.
Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.
May 23rd 2025
Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.
Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.
Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.
May 22nd 2025
Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.
May 20th 2025
Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.
May 19th 2025
During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.
May 15th 2025
Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.
May 14th 2025
Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.
Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.
May 12th 2025
Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.
May 8th 2025
Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.
May 7th 2025
OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.